| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
2-Bromo-4-fluoropyridine does not have a defined pharmacological target of its own, as it is a synthetic intermediate. It serves as a key intermediate in the synthesis of various pharmaceuticals, particularly in the development of anti-cancer and anti-inflammatory drugs. It is also used in the formulation of agrochemicals.
|
|---|---|
| ln Vitro |
In vitro, 2-bromo-4-fluoropyridine is used as a chemical reagent and synthetic intermediate. It can be used to synthesize bioactive molecules through cross-coupling reactions, such as Suzuki coupling or Buchwald-Hartwig amination. As a halogenated pyridine, it is a valuable building block for the construction of drug-like molecules.
|
| ln Vivo |
In vivo activity data for 2-bromo-4-fluoropyridine itself are not available, as the compound is not intended for direct in vivo administration. Rather, it is a precursor used in the synthesis of drug candidates that are subsequently evaluated in animal models.
|
| Enzyme Assay |
For in vitro chemical synthesis, 2-bromo-4-fluoropyridine is used as a building block for cross-coupling reactions. Standard protocols involve reacting the compound with an aryl or heteroaryl boronic acid in the presence of a palladium catalyst and a base in an appropriate solvent at elevated temperatures.
|
| Cell Assay |
For in vitro cell-based experiments, 2-bromo-4-fluoropyridine is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO.
|
| Animal Protocol |
In vivo animal studies using 2-bromo-4-fluoropyridine are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For anti-cancer and anti-inflammatory drugs derived from this building block, efficacy studies would typically be performed in mouse models of the relevant disease.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-bromo-4-fluoropyridine as a standalone compound are not characterized. The compound has a density of 1.699 g/mL at 25°C and should be stored at 0-8°C. It appears as a colorless to light yellow liquid.
|
| Toxicity/Toxicokinetics |
2-Bromo-4-fluoropyridine is a research chemical and should be handled with appropriate laboratory safety precautions. As a halogenated compound, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications.
|
| Additional Infomation |
2-Bromo-4-fluoropyridine (CAS 357927-50-5) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are as a key intermediate in the synthesis of anti-cancer and anti-inflammatory drugs and in the formulation of agrochemicals.
|
| Molecular Formula |
C5H3BRFN
|
|---|---|
| Molecular Weight |
175.99
|
| Exact Mass |
174.943
|
| CAS # |
357927-50-5
|
| PubChem CID |
21885884
|
| Appearance |
Colorless to light yellow liquid（Density：1.699 g/cm3）
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
188.8±20.0 °C at 760 mmHg
|
| Flash Point |
68.0±21.8 °C
|
| Vapour Pressure |
0.8±0.3 mmHg at 25°C
|
| Index of Refraction |
1.534
|
| LogP |
1.47
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
78.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1C([H])=C(C([H])=C([H])N=1)F
|
| InChi Key |
AIEATTRZKVGMBO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H3BrFN/c6-5-3-4(7)1-2-8-5/h1-3H
|
| Chemical Name |
2-bromo-4-fluoropyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (568.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (14.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6821 mL | 28.4107 mL | 56.8214 mL | |
| 5 mM | 1.1364 mL | 5.6821 mL | 11.3643 mL | |
| 10 mM | 0.5682 mL | 2.8411 mL | 5.6821 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
